Background: Long acting antiretroviral drugs represent a promising approach for chronic treatment of HIV infection. Here, we study the efficacy and safety of albuvirtide (ABT), an HIV-1 fusion inhibitor with a half life of 11-12days in human. Methods: ABT was evaluated in a 7-week, open-label and randomized trial, combining with LPV/r. Twenty HIV-1-infected adults were assigned to two dose groups, receiving ABT (160 or 320mg) given weekly and LPV/r given twice daily. Results: At week 7, the decline of HIV-1 RNA from baseline was 1.9 (1.3-2.3) log10 and 2.2 (1.6-2.7) log10 copies/ml, and suppression of HIV-1 RNA to below 50 copies/ml was achieved in 11.1% (1/9) and 55.6% (5/9) patients, for the 160 and 320mg dose group respectively. Conclusion: A clear dose-efficacy correlation of ABT was demonstrated. ABT combining with LPV/r is a promising two-drug regimen to be tested in larger patient population.
Zhang, H., Jin, R., Yao, C., Zhang, T., Wang, M., Xia, W., … Wu, H. (2016). Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients. AIDS Research and Therapy, 13(1). https://doi.org/10.1186/s12981-016-0091-1